NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

Abstract

Patients with bevacizumab-refractory recurrent glioblastoma multiforme (GBM) have a poor prognosis. We propose that instead of continuing on bevacizumab, patients should switch to treatment with Optune™, a novel antimitotic Tumor-Treating Fields (TTFields) therapy approved in the United States for newly diagnosed and recurrent GBM. This would reserve bevacizumab for subsequent disease progression. In this case series, we describe 8 patients with recurrent GBM who had disease progression on bevacizumab, discontinued bevacizumab treatment, and were treated with TTFields therapy alone.

Methods

One patient participated in the phase 3 DCVax-L study for newly diagnosed GBM, receiving dendritic cell-based vaccine versus placebo.

https://www.karger.com/Article/FullText/442196